 |
PDBsum entry 4z0g
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Oxidoreductase
|
PDB id
|
|
|
|
4z0g
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.1.1.1.205
- Imp dehydrogenase.
|
|
 |
 |
 |
 |
 |

Pathway:
|
 |
AMP and GMP Biosynthesis
|
 |
 |
 |
 |
 |
Reaction:
|
 |
IMP + NAD+ + H2O = XMP + NADH + H+
|
 |
 |
 |
 |
 |
IMP
|
+
|
NAD(+)
Bound ligand (Het Group name = )
matches with 95.83% similarity
|
+
|
H2O
|
=
|
XMP
|
+
|
NADH
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Nat Commun
6:8923
(2015)
|
|
PubMed id:
|
|
|
|
|
| |
|
Guanine nucleotide binding to the Bateman domain mediates the allosteric inhibition of eukaryotic IMP dehydrogenases.
|
|
R.M.Buey,
R.Ledesma-Amaro,
A.Velázquez-Campoy,
M.Balsera,
M.Chagoyen,
J.M.de Pereda,
J.L.Revuelta.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Inosine-5'-monophosphate dehydrogenase (IMPDH) plays key roles in purine
nucleotide metabolism and cell proliferation. Although IMPDH is a widely studied
therapeutic target, there is limited information about its physiological
regulation. Using Ashbya gossypii as a model, we describe the molecular
mechanism and the structural basis for the allosteric regulation of IMPDH by
guanine nucleotides. We report that GTP and GDP bind to the regulatory Bateman
domain, inducing octamers with compromised catalytic activity. Our data suggest
that eukaryotic and prokaryotic IMPDHs might have developed different regulatory
mechanisms, with GTP/GDP inhibiting only eukaryotic IMPDHs. Interestingly,
mutations associated with human retinopathies map into the guanine
nucleotide-binding sites including a previously undescribed non-canonical site
and disrupt allosteric inhibition. Together, our results shed light on the
mechanisms of the allosteric regulation of enzymes mediated by Bateman domains
and provide a molecular basis for certain retinopathies, opening the door to new
therapeutic approaches.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |